Company: NDRA
Filing Date: 2025-07-25
Form Type: S-1/A
Source: 0001654954-25-008477
Chunk: 43

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-07-25
Form: S-1/A
Chunk 43
---
 24, 2025, we would purchase approximately 763 bitcoins. Initially, the Company expects to utilize all of its cash allocated to its cryptocurrency treasury strategy to purchase bitcoin; however, in consultation with Arca and the Advisory Board, we intend to continuously monitor cryptocurrency market conditions and consider whether any other cryptocurrencies that are intrinsically linked to a blockchain system, and the value of which is derived from or is reasonably expected to be derived from the use of a blockchain system, would be beneficial to add to the Company’s cryptocurrency portfolio, to the extent we determine compliant with federal rules and regulations and not giving rise to a requirement that the Company register as an investment company under the 1940 Act.

The expected use of net proceeds from this offering represents our intentions based upon our present plans and business conditions. Other than the portion of net proceeds to be used to purchase cryptocurrency, we cannot predict with certainty all of the particular uses for the proceeds of this offering or the exact amounts that we will actually spend on the uses set forth above.

Pending our use of the net proceeds from this offering as described above, we intend to maintain any net proceeds as cash deposits or cash management instruments, such as U.S. government securities or money market mutual funds. To the extent that any of our assets allocated to our cryptocurrency treasury strategy is not held in bitcoin or other cryptocurrencies, it will be held in cash deposits or cash management instruments, such as U.S. government securities or money market mutual funds.

| 27 |

<div align='center'>CAPITALIZATION</div>

The following table sets forth our capitalization as of March 31, 2025:

| · | on an actual basis; and                                                                                                                                                                  |
| · | on an as adjusted basis, after giving effect to the application of the net proceeds of this offering after deducting the Underwriter fees and estimated offering expenses payable by us. |

The information set forth in the following table should be read in conjunction with and is qualified in its entirety by “Use of Proceeds” above, as well as our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and the notes to those financial statements incorporated by reference in this prospectus. See “The Offering” in this prospectus for information relating to the expected number of shares of our common stock to be outstanding after this offering. Our capitalization following the closing of this offering will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

|                                                                                                                                                             |     | As